

---

## Overview

### Useful For

Evaluating patients with a personal or family history suggestive of Birt-Hogg-Dube (BHD) syndrome

Establishing a diagnosis of BHD syndrome allowing for targeted cancer surveillance based on associated risks

Identifying variants within genes known to be associated with increased risk for BHD syndrome allowing for predictive testing of at-risk family members

### Genetics Test Information

[This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in the \*FLCN\* gene associated with Birt-Hogg-Dube \(BHD\) syndrome. See Method Description for additional details.](#)

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for BHD syndrome.

### Special Instructions

- [Molecular Genetics: Inherited Cancer Syndromes Patient Information](#)
- [Informed Consent for Genetic Testing](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)

### Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

### NY State Available

Yes

---

## Specimen

### Specimen Type

Varies

### Ordering Guidance

For a comprehensive hereditary renal cancer gene panel that includes testing for *FLCN*, consider RENC / Hereditary Renal Cancer Panel, Varies.

Testing for the *FLCN* gene as part of a customized panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for this gene. For more information see FMTT / Familial Mutation, Targeted Testing, Varies. [To obtain more information about this testing option, call 800-533-1710.](#)

**Shipping Instructions**

Specimen preferred to arrive within 96 hours of collection.

**Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

**Specimen Type:** Whole blood

**Container/Tube:**

**Preferred:** Lavender top (EDTA) or yellow top (ACD)

**Acceptable:** Any anticoagulant

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

**Specimen Stability Information:** Ambient (preferred) 4 days/Refrigerated

**Forms**

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:

[-Informed Consent for Genetic Testing \(T576\)](#)

[-Informed Consent for Genetic Testing \(Spanish\) \(T826\)](#)

[2. Molecular Genetics: Inherited Cancer Syndromes Patient Information Sheet \(T519\)](#)

3. If not ordering electronically, complete, print, and send a [Oncology Test Request \(T729\)](#) with the specimen.

**Specimen Minimum Volume**

1 mL

**Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

**Clinical & Interpretive****Clinical Information**

Germline variants in the *FLCN* gene are associated with Birt-Hogg-Dube (BHD) syndrome. BHD syndrome is characterized

---

by cutaneous manifestations (fibrofolliculomas, trichodiscomas/angiofibromas, perifollicular fibromas, and acrochordons), pulmonary cysts/history of pneumothorax, and various types of renal tumors. BHD syndrome is inherited in an autosomal dominant manner and the penetrance is considered to be very high.(1-6)

While there is no consensus on clinical surveillance of BHD syndrome, many recommendations have been put forth for the individual manifestations of the condition by different groups, such as the National Cancer Institute.(4-6)

**Reference Values**

An interpretive report will be provided.

**Interpretation**

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(7) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

**Cautions**

Clinical Correlations:

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

To discuss the availability of additional testing options or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at [800-533-1710](tel:800-533-1710).

Technical Limitations:

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

Deletion/Duplication Analysis:

This analysis targets single and multi-exon deletions/duplications; however, in some instances single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural

---

rearrangements (such as translocations and inversions) may not be detected.

This test is not designed to detect low levels of mosaicism or differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

For detailed information regarding gene specific performance and technical limitations, see Method Description or contact a laboratory genetic counselor.

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

#### Reclassification of Variants:

Currently, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare providers to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time.

#### Variant Evaluation:

Evaluation and categorization of variants are performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.<sup>(7)</sup> Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgement.

#### Clinical Reference

1. Sattler EC, Steinlein OK: Birt-Hogg-Dube syndrome. In: Adam MP, [Everman DB](#), [Mirzaa GM](#), et al, eds. GeneReviews. [Internet]. University of Washington, Seattle; 2006. Updated January 30, 2020. Accessed November 8, 2022. Available at: [www.ncbi.nlm.nih.gov/books/NBK1522/](http://www.ncbi.nlm.nih.gov/books/NBK1522/)
2. Houweling AC, Gijzen LM, Joneker MA, et al: Renal cancer and pneumothorax risk in Birt-Hogg-Dube syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. *Br J Cancer*. 2011 Dec 6;105(12):1912-1919
3. Schmidt LS, Nickerson ML, Warren MB, et al: Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube Syndrome. *Am J Hum Genet*. 2005 Jun;76(6):1023-1033
4. Stamatakis L, Metwalli AR, Middelton LA, Linehan WM: Diagnosis and management of BHD-associated kidney cancer. *Fam Cancer*. 2013 Sep;12(3):397-402
5. Farrant PBJ, Emerson R: Letter: hyfrecreation and curettage as a treatment for fibrofolliculomas in Birt-Hogg-Dube syndrome. *Dermatol Surg*. 2007 Oct;33(10):1287-1288
6. Kim D, Wysong A, Teng JM, Rahman Z: Laser-assisted delivery of topical rapamycin: mTOR inhibition for Birt-Hogg-Dube syndrome. *Dermatol Surg*. 2019 Dec;45(12):1713-1715

---

7. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424

## Performance

### Method Description

Next-generation sequencing (NGS) and/or Sanger sequencing are performed to test for the presence of variants in coding regions and intron/exon boundaries of the *FLCN* gene, as well as some other regions that have known pathogenic variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletions-insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in the *FLCN* gene.

There may be regions of the *FLCN* gene that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. The reference transcript for *FLCN* gene is NM\_144997.7. Reference transcript numbers may be updated due to transcript re-versioning. Always refer to the final patient report for gene transcript information referenced at the time of testing.(Unpublished Mayo method)

Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

### PDF Report

Supplemental

### Day(s) Performed

Varies

### Report Available

21 to 28 days

### Specimen Retention Time

Whole Blood: 2 weeks (if available); Extracted DNA: 3 months

### Performing Laboratory Location

Rochester

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

### CPT Code Information

81479

### LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
BHDZ	FLCN Full Gene Analysis	94232-6

Result ID	Test Result Name	Result LOINC® Value
614635	Test Description	62364-5
614636	Specimen	31208-2
614637	Source	31208-2
614638	Result Summary	50397-9
614639	Result	82939-0
614640	Interpretation	69047-9
614641	Resources	99622-3
614642	Additional Information	48767-8
614643	Method	85069-3
614644	Genes Analyzed	48018-6
614645	Disclaimer	62364-5
614646	Released By	18771-6